Effect of antibiotic therapy on the prognosis of ventilator-associated pneumonia caused by Stenotrophomonas maltophilia.
Antibiotic therapy
Outcome
Stenotrophomonas maltophilia
Ventilator-associated pneumonia
Journal
Annals of intensive care
ISSN: 2110-5820
Titre abrégé: Ann Intensive Care
Pays: Germany
ID NLM: 101562873
Informations de publication
Date de publication:
26 Nov 2021
26 Nov 2021
Historique:
received:
04
06
2021
accepted:
12
11
2021
entrez:
26
11
2021
pubmed:
27
11
2021
medline:
27
11
2021
Statut:
epublish
Résumé
Ventilator-associated pneumonia (VAP) caused by Stenotrophomonas maltophilia is poorly described in the literature. However, it has been shown to be associated with increased morbidity and mortality. Probabilistic antibiotic therapy against S. maltophilia is often ineffective as this pathogen is resistant to many antibiotics. There is no consensus at present on the best therapeutic strategy to adopt (class of antibiotics, antibiotic combination, dosage, treatment duration). The aim of this study was to evaluate the effect of antibiotic therapy strategy on the prognosis of patients with VAP caused by S. maltophilia. This retrospective study evaluated all consecutive patients who developed VAP caused by S. maltophilia between 2010 and 2018 while hospitalized in the intensive care unit (ICU) of a French university hospital in Reunion Island, in the Indian Ocean region. A total of 130 patients with a median Simplified Acute Physiology Score II of 58 [43-73] had VAP caused by S. maltophilia after a median duration of mechanical ventilation of 12 [5-18] days. Ventilator-associated pneumonia was polymicrobial in 44.6% of cases, and ICU mortality was 50.0%. After multivariate Cox regression analysis, the factors associated with increased ICU mortality were older age (hazard ratio (HR): 1.03; 95% CI 1.01-1.04, p = 0.001) and high Sequential Organ Failure Assessment score on the day of VAP onset (HR: 1.08; 95% CI 1.03-1.14, p = 0.002). Appropriate antibiotic therapy, and in particular trimethoprim-sulfamethoxazole, was associated with decreased ICU mortality (HR: 0.42; 95% CI 0.24-0.74, p = 0.003) and decreased hospital mortality (HR: 0.47; 95% CI 0.28-0.79, p = 0.04). Time to start of appropriate antibiotic therapy, combination therapy, and duration of appropriate antibiotic therapy had no effect on ICU mortality (p > 0.5). In our study, appropriate antibiotic therapy, and in particular trimethoprim-sulfamethoxazole, was associated with decreased ICU and hospital mortality in patients with VAP caused by S. maltophilia.
Sections du résumé
BACKGROUND
BACKGROUND
Ventilator-associated pneumonia (VAP) caused by Stenotrophomonas maltophilia is poorly described in the literature. However, it has been shown to be associated with increased morbidity and mortality. Probabilistic antibiotic therapy against S. maltophilia is often ineffective as this pathogen is resistant to many antibiotics. There is no consensus at present on the best therapeutic strategy to adopt (class of antibiotics, antibiotic combination, dosage, treatment duration). The aim of this study was to evaluate the effect of antibiotic therapy strategy on the prognosis of patients with VAP caused by S. maltophilia.
RESULTS
RESULTS
This retrospective study evaluated all consecutive patients who developed VAP caused by S. maltophilia between 2010 and 2018 while hospitalized in the intensive care unit (ICU) of a French university hospital in Reunion Island, in the Indian Ocean region. A total of 130 patients with a median Simplified Acute Physiology Score II of 58 [43-73] had VAP caused by S. maltophilia after a median duration of mechanical ventilation of 12 [5-18] days. Ventilator-associated pneumonia was polymicrobial in 44.6% of cases, and ICU mortality was 50.0%. After multivariate Cox regression analysis, the factors associated with increased ICU mortality were older age (hazard ratio (HR): 1.03; 95% CI 1.01-1.04, p = 0.001) and high Sequential Organ Failure Assessment score on the day of VAP onset (HR: 1.08; 95% CI 1.03-1.14, p = 0.002). Appropriate antibiotic therapy, and in particular trimethoprim-sulfamethoxazole, was associated with decreased ICU mortality (HR: 0.42; 95% CI 0.24-0.74, p = 0.003) and decreased hospital mortality (HR: 0.47; 95% CI 0.28-0.79, p = 0.04). Time to start of appropriate antibiotic therapy, combination therapy, and duration of appropriate antibiotic therapy had no effect on ICU mortality (p > 0.5).
CONCLUSION
CONCLUSIONS
In our study, appropriate antibiotic therapy, and in particular trimethoprim-sulfamethoxazole, was associated with decreased ICU and hospital mortality in patients with VAP caused by S. maltophilia.
Identifiants
pubmed: 34825962
doi: 10.1186/s13613-021-00950-1
pii: 10.1186/s13613-021-00950-1
pmc: PMC8626555
doi:
Types de publication
Journal Article
Langues
eng
Pagination
160Informations de copyright
© 2021. The Author(s).
Références
Eur J Clin Microbiol Infect Dis. 2017 Nov;36(11):2231-2235
pubmed: 28669016
Infect Control Hosp Epidemiol. 2009 Dec;30(12):1193-202
pubmed: 19852664
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Int J Antimicrob Agents. 2013 Apr;41(4):301-10
pubmed: 23410791
Anaesth Crit Care Pain Med. 2018 Dec;37(6):607-614
pubmed: 30580775
Ann Intensive Care. 2020 Aug 3;10(1):101
pubmed: 32748025
Antimicrob Agents Chemother. 2014;58(1):176-82
pubmed: 24145530
J Antimicrob Chemother. 2019 Jul 1;74(7):2055-2059
pubmed: 30945726
Antibiotics (Basel). 2019 Feb 08;8(1):
pubmed: 30744080
Expert Rev Anti Infect Ther. 2015 May;13(5):567-73
pubmed: 25850806
Trials. 2017 Jan 23;18(1):37
pubmed: 28114979
Cochrane Database Syst Rev. 2015 Aug 24;(8):CD007577
pubmed: 26301604
Cochrane Database Syst Rev. 2014 Jan 07;(1):CD003344
pubmed: 24395715
J Infect. 2020 Mar;80(3):279-285
pubmed: 31682878
Infect Dis (Lond). 2016 Oct;48(10):738-43
pubmed: 27207483
Eur Respir J. 2005 May;25(5):911-4
pubmed: 15863651
Clin Infect Dis. 2016 Sep 1;63(5):e61-e111
pubmed: 27418577
Clin Microbiol Infect. 2019 May;25(5):546-554
pubmed: 30448331
Crit Care. 2006;10(5):R143
pubmed: 17026755
Eur J Clin Microbiol Infect Dis. 2012 Jul;31(7):1419-28
pubmed: 22057419
Clin Infect Dis. 2002 Aug 1;35(3):228-35
pubmed: 12115086
Clin Microbiol Rev. 2006 Oct;19(4):637-57
pubmed: 17041138
Crit Care. 2019 Nov 21;23(1):371
pubmed: 31752976
JAMA. 2003 Nov 19;290(19):2588-98
pubmed: 14625336
Future Microbiol. 2009 Nov;4(9):1103-9
pubmed: 19895214
Eur Respir J. 2017 Oct 19;50(4):
pubmed: 29051270
J Clin Med. 2020 Jan 19;9(1):
pubmed: 31963877
Expert Rev Anti Infect Ther. 2018 Feb;16(2):89-110
pubmed: 29310479